CN Patent

CN1822841A — 抗冠状病毒剂

Assigned to Arigen Pharmaceuticals Inc · Expires 2006-08-23 · 20y expired

What this patent protects

本发明提供以奈非那韦为代表的化合物或它的药学上允许的盐作为有效成分的抗冠状病毒剂，以该抗冠状病毒剂作为有效成分的抗SARS剂、和使用该抗SARS剂的SARS治疗方法。

USPTO Abstract

本发明提供以奈非那韦为代表的化合物或它的药学上允许的盐作为有效成分的抗冠状病毒剂，以该抗冠状病毒剂作为有效成分的抗SARS剂、和使用该抗SARS剂的SARS治疗方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN1822841A
Jurisdiction
CN
Classification
—
Expires
2006-08-23
Drug substance claim
No
Drug product claim
No
Assignee
Arigen Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.